KA Antons, CD Williams, SK Baker, PS … - The American journal of medicine, 2006 - Elsevier Fear of muscle toxicity remains a major reason that patients with hyperlipidemia
are undertreated. Recent evaluations of statin-induced rhabdomyolysis offer new
insights on the clinical management of both muscle symptoms and ... Cited by 71 - Related articles - All 4 versions
- ►asnjournals.org IM Wahba, RH Mak - Clinical Journal of the American Society of Nephrology, 2007 - Am Soc Nephrol There is an epidemic of obesity and the metabolic syndrome in the United States
and across the world. Both entities are associated with high mortality, mainly
as a result of cardiovascular disease. The epidemic of obesity has been ... Cited by 43 - Related articles - BL Direct - All 4 versions
MH Davidson - Expert Opin. Drug Saf., 2006 - Informa Pharma Science Patients with the metabolic syndrome and/or Type 2 diabetes mellitus continue to
have a high risk of coronary heart disease (CHD) and progression of
atherosclerotic lesions despite aggressive statin therapy. Although the ... Cited by 37 - Related articles - BL Direct - All 7 versions
- ►nursing2008.com GM Keating, KF Croom - Drugs, 2007 - ingentaconnect.com 0012-6667/07/0001-0121/$49.95/0 2007 Adis Data Information BV. All rights
reserved. ... A Review of its Use in Primary Dyslipidaemia, the Metabolic
Syndrome and Type 2 Diabetes Mellitus ... Gillian M. Keating and ... Cited by 37 - Related articles - BL Direct - All 10 versions
A Corsini, S Bellosta, MH Davidson - The American journal of cardiology, 2005 - Elsevier Concomitant use of a fibrate and a statin may offer a therapeutic advantage to
patients with dyslipidemia, especially in patients whose low-density lipoprotein
cholesterol is controlled by statins but whose high-density lipoprotein ... Cited by 25 - Related articles - All 6 versions
- ►solgar.co.il [PDF] BA Golomb, MA Evans - Am J Cardiovasc Drugs, 2008 - canadiancpd.medscape.com HMG-CoA reductase inhibitors (statins) are a widely used class of drug, and like
all medications, have potential for adverse effects (AEs). Here we review the
statin AE literature, first focusing on muscle AEs as the most reported ... Cited by 12 - Related articles - All 15 versions
- ►ksu.edu.sa [PDF] SK Baker, IA Samjoo - The Canadian Journal of Neurological Sciences, 2008 - CJNS The statins, as a class, are one of the most widely prescribed medications. An
estimated 25 million patients worldwide (13 million Americans) are treated with
statins of the 200 million patients worldwide (36 million patients in the ... Cited by 7 - Related articles - BL Direct - All 3 versions
JG Robinson - Expert Opin. Pharmacother., 2007 - informahealthcare.com Simvastatin is lipophilic statin with a short half-life that is primarily
metabolized by CYP450 3A4. At doses of 5 – 80 mg, simvastatin lowers LDL
cholesterol by 25 – 50%. Simvastatin has been shown to reduce the risk of ... Cited by 7 - Related articles - BL Direct - All 6 versions
MAE AEs, D Response - medscape.com When possible AEs arise in a patient receiving any drug, the risk-benefit
balance of treatment should be reassessed. Statins are a linchpin of current
approaches to cardiovascular protection; however, the AEs of statins are ... Related articles
D Deme, A Al-Hadad, T Varga, E Szántó, K … - Clinical and Experimental Medical Journal, 2009 - akademiai.com Abbreviations RML = rhabdomyolysis; SIM = simvastatin; ASAT(GOT) =
aspartate-amino-transferase; BUN = blood urea nitrogen; CVP = central venous
pressure; CYP3A4 = cytochrome P450 3A4 microsomal enzyme; CK = crea- tine ... Related articles - All 3 versions
